Skip to main content
Top
Published in: Cancer and Metastasis Reviews 3/2019

01-09-2019

Differential roles of protease isoforms in the tumor microenvironment

Authors: Chamikara Liyanage, Achala Fernando, Jyotsna Batra

Published in: Cancer and Metastasis Reviews | Issue 3/2019

Login to get access

Abstract

Alternative splicing of precursor mRNA is a key mediator of gene expression regulation leading to greater diversity of the proteome in complex organisms. Systematic sequencing of the human genome and transcriptome has led to our understanding of how alternative splicing of critical genes leads to multiple pathological conditions such as cancer. For many years, proteases were known only for their roles as proteolytic enzymes, acting to regulate/process proteins associated with diverse cellular functions. However, the differential expression and altered function of various protease isoforms, such as (i) anti-apoptotic activities, (ii) mediating intercellular adhesion, and (iii) modifying the extracellular matrix, are evidence of their specific contribution towards shaping the tumor microenvironment. Revealing the alternative splicing of protease genes and characterization of their protein products/isoforms with distinct and opposing functions creates a platform to understand how protease isoforms contribute to specific cancer hallmarks. Here, in this review, we address cancer-specific isoforms produced by the alternative splicing of proteases and their distinctive roles in the tumor microenvironment.
Literature
2.
go back to reference Puente, X. S., Ordóñez, G. R., & López-Otín, C. (2008). Protease genomics and the cancer degradome. In G. Høyer-Hansen, D. Edwards, F. Blasi, & B. F. Sloane (Eds.), The cancer degradome (pp. 3–15). New York: Springer.CrossRef Puente, X. S., Ordóñez, G. R., & López-Otín, C. (2008). Protease genomics and the cancer degradome. In G. Høyer-Hansen, D. Edwards, F. Blasi, & B. F. Sloane (Eds.), The cancer degradome (pp. 3–15). New York: Springer.CrossRef
5.
go back to reference Buo, L., Aasen, A. O., Karlsrud, T. S., Johansen, H. T., & Sivertsen, S. M. (1990). The role of proteases in the growth, invasion and spread of cancer cells. Tidsskrift for den Norske Lægeforening, 110(29), 3753–3756.PubMed Buo, L., Aasen, A. O., Karlsrud, T. S., Johansen, H. T., & Sivertsen, S. M. (1990). The role of proteases in the growth, invasion and spread of cancer cells. Tidsskrift for den Norske Lægeforening, 110(29), 3753–3756.PubMed
6.
go back to reference Duffy, M. J. (1992). The role of proteolytic enzymes in cancer invasion and metastasis. Clinical & Experimental Metastasis, 10(3), 145–155.CrossRef Duffy, M. J. (1992). The role of proteolytic enzymes in cancer invasion and metastasis. Clinical & Experimental Metastasis, 10(3), 145–155.CrossRef
8.
go back to reference Zucker, S. (1988). A critical appraisal of the role of proteolytic enzymes in cancer invasion: emphasis on tumor surface proteinases. Cancer Investigation, 6(2), 219–231.PubMedCrossRef Zucker, S. (1988). A critical appraisal of the role of proteolytic enzymes in cancer invasion: emphasis on tumor surface proteinases. Cancer Investigation, 6(2), 219–231.PubMedCrossRef
9.
go back to reference Yang, Y., Hong, H., Zhang, Y., & Cai, W. (2009). Molecular imaging of proteases in cancer. Cancer Growth Metastasis, 2, 13–27.PubMedCrossRef Yang, Y., Hong, H., Zhang, Y., & Cai, W. (2009). Molecular imaging of proteases in cancer. Cancer Growth Metastasis, 2, 13–27.PubMedCrossRef
19.
go back to reference Webber, M. M., Waghray, A., & Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clinical Cancer Research, 1(10), 1089–1094.PubMed Webber, M. M., Waghray, A., & Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clinical Cancer Research, 1(10), 1089–1094.PubMed
23.
go back to reference Heuze, N., Olayat, S., Gutman, N., Zani, M. L., & Courty, Y. (1999). Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. Cancer Research, 59(12), 2820–2824.PubMed Heuze, N., Olayat, S., Gutman, N., Zani, M. L., & Courty, Y. (1999). Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. Cancer Research, 59(12), 2820–2824.PubMed
24.
go back to reference Whitbread, A. K., Veveris-Lowe, T. L., Dong, Y., Tan, O. L., Gardiner, R., Samaratunga, H. M., et al. (2010). Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 391(4), 461–466. https://doi.org/10.1515/BC.2010.043.CrossRefPubMed Whitbread, A. K., Veveris-Lowe, T. L., Dong, Y., Tan, O. L., Gardiner, R., Samaratunga, H. M., et al. (2010). Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 391(4), 461–466. https://​doi.​org/​10.​1515/​BC.​2010.​043.CrossRefPubMed
25.
go back to reference Tanaka, T., Isono, T., Yoshiki, T., Yuasa, T., & Okada, Y. (2000). A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Research, 60(1), 56–59.PubMed Tanaka, T., Isono, T., Yoshiki, T., Yuasa, T., & Okada, Y. (2000). A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Research, 60(1), 56–59.PubMed
36.
go back to reference Magklara, A., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G. M., Fracchioli, S., et al. (2001). The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clinical Cancer Research, 7(4), 806–811.PubMed Magklara, A., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G. M., Fracchioli, S., et al. (2001). The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clinical Cancer Research, 7(4), 806–811.PubMed
40.
go back to reference Fujise, N., Nanashim, A., Taniguchi, Y., Matsuo, S., Hatano, K., Matsumoto, Y., et al. (2000). Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer, 27(1), 19–26.PubMedCrossRef Fujise, N., Nanashim, A., Taniguchi, Y., Matsuo, S., Hatano, K., Matsumoto, Y., et al. (2000). Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer, 27(1), 19–26.PubMedCrossRef
41.
go back to reference Krueger, S., Haeckel, C., Buehling, F., & Roessner, A. (1999). Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Research, 59(23), 6010–6014.PubMed Krueger, S., Haeckel, C., Buehling, F., & Roessner, A. (1999). Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Research, 59(23), 6010–6014.PubMed
42.
go back to reference Rempel, S. A., Rosenblum, M. L., Mikkelsen, T., Yan, P. S., Ellis, K. D., Golembieski, W. A., et al. (1994). Cathepsin B expression and localization in glioma progression and invasion. Cancer Research, 54(23), 6027–6031.PubMed Rempel, S. A., Rosenblum, M. L., Mikkelsen, T., Yan, P. S., Ellis, K. D., Golembieski, W. A., et al. (1994). Cathepsin B expression and localization in glioma progression and invasion. Cancer Research, 54(23), 6027–6031.PubMed
48.
go back to reference Wu, D., Wang, H. J., Li, Z. N., Wang, L. H., Zheng, F. Y., Jiang, J., et al. (2012). Cathepsin B may be a potential biomarker in cervical cancer. Histology and Histopathology, 27(1), 79–87.PubMed Wu, D., Wang, H. J., Li, Z. N., Wang, L. H., Zheng, F. Y., Jiang, J., et al. (2012). Cathepsin B may be a potential biomarker in cervical cancer. Histology and Histopathology, 27(1), 79–87.PubMed
49.
go back to reference Mehtani, S., Gong, Q., Panella, J., Subbiah, S., Peffley, D. M., & Frankfater, A. (1998). In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells. The Journal of Biological Chemistry, 273(21), 13236–13244. https://doi.org/10.1074/jbc.273.21.13236.CrossRefPubMed Mehtani, S., Gong, Q., Panella, J., Subbiah, S., Peffley, D. M., & Frankfater, A. (1998). In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells. The Journal of Biological Chemistry, 273(21), 13236–13244. https://​doi.​org/​10.​1074/​jbc.​273.​21.​13236.CrossRefPubMed
51.
go back to reference Rescheleit, D. K., Rommerskirch, W. J., & Wiederanders, B. (1996). Sequence analysis and distribution of two new human cathepsin L splice variants. FEBS Letters, 394(3), 345–348.PubMedCrossRef Rescheleit, D. K., Rommerskirch, W. J., & Wiederanders, B. (1996). Sequence analysis and distribution of two new human cathepsin L splice variants. FEBS Letters, 394(3), 345–348.PubMedCrossRef
55.
go back to reference Chauhan, S. S., Popescu, N. C., Ray, D., Fleischmann, R., Gottesman, M. M., & Troen, B. R. (1993). Cloning, genomic organization, and chromosomal localization of human cathepsin L. The Journal of Biological Chemistry, 268(2), 1039–1045.PubMed Chauhan, S. S., Popescu, N. C., Ray, D., Fleischmann, R., Gottesman, M. M., & Troen, B. R. (1993). Cloning, genomic organization, and chromosomal localization of human cathepsin L. The Journal of Biological Chemistry, 268(2), 1039–1045.PubMed
56.
go back to reference Estrov, Z., Thall, P. F., Talpaz, M., Estey, E. H., Kantarjian, H. M., Andreeff, M., et al. (1998). Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood, 92(9), 3090–3097.PubMedCrossRef Estrov, Z., Thall, P. F., Talpaz, M., Estey, E. H., Kantarjian, H. M., Andreeff, M., et al. (1998). Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood, 92(9), 3090–3097.PubMedCrossRef
57.
go back to reference Faderl, S., Thall, P. F., Kantarjian, H. M., Talpaz, M., Harris, D., Van, Q., et al. (1999). Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clinical Cancer Research, 5(12), 4041–4047.PubMed Faderl, S., Thall, P. F., Kantarjian, H. M., Talpaz, M., Harris, D., Van, Q., et al. (1999). Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clinical Cancer Research, 5(12), 4041–4047.PubMed
59.
62.
go back to reference Droin, N., Beauchemin, M., Solary, E., & Bertrand, R. (2000). Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade. Cancer Research, 60(24), 7039–7047.PubMed Droin, N., Beauchemin, M., Solary, E., & Bertrand, R. (2000). Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade. Cancer Research, 60(24), 7039–7047.PubMed
70.
go back to reference O’Donovan, N., Crown, J., Stunell, H., Hill, A. D., McDermott, E., O’Higgins, N., et al. (2003). Caspase 3 in breast cancer. Clinical Cancer Research, 9(2), 738–742.PubMed O’Donovan, N., Crown, J., Stunell, H., Hill, A. D., McDermott, E., O’Higgins, N., et al. (2003). Caspase 3 in breast cancer. Clinical Cancer Research, 9(2), 738–742.PubMed
72.
go back to reference Woenckhaus, C., Giebel, J., Failing, K., Fenic, I., Dittberner, T., & Poetsch, M. (2003). Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? The Journal of Pathology, 201(2), 278–287. https://doi.org/10.1002/path.1424.CrossRefPubMed Woenckhaus, C., Giebel, J., Failing, K., Fenic, I., Dittberner, T., & Poetsch, M. (2003). Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? The Journal of Pathology, 201(2), 278–287. https://​doi.​org/​10.​1002/​path.​1424.CrossRefPubMed
73.
84.
go back to reference Chalfant, C. E., Rathman, K., Pinkerman, R. L., Wood, R. E., Obeid, L. M., Ogretmen, B., et al. (2002). De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. The Journal of Biological Chemistry, 277(15), 12587–12595. https://doi.org/10.1074/jbc.M112010200.CrossRefPubMed Chalfant, C. E., Rathman, K., Pinkerman, R. L., Wood, R. E., Obeid, L. M., Ogretmen, B., et al. (2002). De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. The Journal of Biological Chemistry, 277(15), 12587–12595. https://​doi.​org/​10.​1074/​jbc.​M112010200.CrossRefPubMed
87.
go back to reference Shultz, J. C., Goehe, R. W., Murudkar, C. S., Wijesinghe, D. S., Mayton, E. K., Massiello, A., et al. (2011). SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Molecular Cancer Research, 9(7), 889–900. https://doi.org/10.1158/1541-7786.MCR-11-0061.CrossRefPubMed Shultz, J. C., Goehe, R. W., Murudkar, C. S., Wijesinghe, D. S., Mayton, E. K., Massiello, A., et al. (2011). SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Molecular Cancer Research, 9(7), 889–900. https://​doi.​org/​10.​1158/​1541-7786.​MCR-11-0061.CrossRefPubMed
90.
go back to reference Zhang, D., Liu, H., Yang, B., Hu, J., & Cheng, Y. (2019). L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways. Bioscience Reports, 39(5). https://doi.org/10.1042/BSR20190469. Zhang, D., Liu, H., Yang, B., Hu, J., & Cheng, Y. (2019). L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways. Bioscience Reports, 39(5). https://​doi.​org/​10.​1042/​BSR20190469.
94.
go back to reference Muhlethaler-Mottet, A., Flahaut, M., Bourloud, K. B., Nardou, K., Coulon, A., Liberman, J., et al. (2011). Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death & Disease, 2, e125. https://doi.org/10.1038/cddis.2011.8.CrossRef Muhlethaler-Mottet, A., Flahaut, M., Bourloud, K. B., Nardou, K., Coulon, A., Liberman, J., et al. (2011). Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death & Disease, 2, e125. https://​doi.​org/​10.​1038/​cddis.​2011.​8.CrossRef
103.
go back to reference Duhachek Muggy, S. (2014). Multiple isoforms of ADAM12 in breast cancer: differential regulation of expression and unique roles in cancer progression. Kansas State University, K-State Electronic Theses, Dissertations, and Reports: 2004 Duhachek Muggy, S. (2014). Multiple isoforms of ADAM12 in breast cancer: differential regulation of expression and unique roles in cancer progression. Kansas State University, K-State Electronic Theses, Dissertations, and Reports: 2004
106.
go back to reference Carl-McGrath, S., Lendeckel, U., Ebert, M., Roessner, A., & Rocken, C. (2005). The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. International Journal of Oncology, 26(1), 17–24.PubMed Carl-McGrath, S., Lendeckel, U., Ebert, M., Roessner, A., & Rocken, C. (2005). The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. International Journal of Oncology, 26(1), 17–24.PubMed
109.
113.
go back to reference Hedstrom, L. (2002). Serine protease mechanism and specificity. Chemical Reviews, 102(12), 4501–4524.PubMedCrossRef Hedstrom, L. (2002). Serine protease mechanism and specificity. Chemical Reviews, 102(12), 4501–4524.PubMedCrossRef
115.
go back to reference Borgono, C. A., Michael, I. P., & Diamandis, E. P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Molecular Cancer Research, 2(5), 257–280.PubMed Borgono, C. A., Michael, I. P., & Diamandis, E. P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Molecular Cancer Research, 2(5), 257–280.PubMed
123.
go back to reference Obiezu, C. V., Soosaipillai, A., Jung, K., Stephan, C., Scorilas, A., Howarth, D. H., et al. (2002). Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clinical Chemistry, 48(8), 1232–1240.PubMed Obiezu, C. V., Soosaipillai, A., Jung, K., Stephan, C., Scorilas, A., Howarth, D. H., et al. (2002). Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clinical Chemistry, 48(8), 1232–1240.PubMed
126.
go back to reference Obiezu, C. V., & Diamandis, E. P. (2000). An alternatively spliced variant of KLK4 expressed in prostatic tissue. Clinical Biochemistry, 33(7), 599–600.PubMedCrossRef Obiezu, C. V., & Diamandis, E. P. (2000). An alternatively spliced variant of KLK4 expressed in prostatic tissue. Clinical Biochemistry, 33(7), 599–600.PubMedCrossRef
127.
go back to reference Dong, Y., Kaushal, A., Bui, L., Chu, S., Fuller, P. J., Nicklin, J., et al. (2001). Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clinical Cancer Research, 7(8), 2363–2371.PubMed Dong, Y., Kaushal, A., Bui, L., Chu, S., Fuller, P. J., Nicklin, J., et al. (2001). Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clinical Cancer Research, 7(8), 2363–2371.PubMed
128.
go back to reference Korkmaz, K. S., Korkmaz, C. G., Pretlow, T. G., & Saatcioglu, F. (2001). Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. DNA and Cell Biology, 20(7), 435–445. https://doi.org/10.1089/104454901750361497.CrossRefPubMed Korkmaz, K. S., Korkmaz, C. G., Pretlow, T. G., & Saatcioglu, F. (2001). Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. DNA and Cell Biology, 20(7), 435–445. https://​doi.​org/​10.​1089/​1044549017503614​97.CrossRefPubMed
130.
go back to reference Veveris-Lowe, T. L., Lawrence, M. G., Collard, R. L., Bui, L., Herington, A. C., Nicol, D. L., et al. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocrine-Related Cancer, 12(3), 631–643. https://doi.org/10.1677/erc.1.00958.CrossRefPubMed Veveris-Lowe, T. L., Lawrence, M. G., Collard, R. L., Bui, L., Herington, A. C., Nicol, D. L., et al. (2005). Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocrine-Related Cancer, 12(3), 631–643. https://​doi.​org/​10.​1677/​erc.​1.​00958.CrossRefPubMed
137.
139.
go back to reference Jin, H., Nagai, N., Shigemasa, K., Gu, L., Tanimoto, H., Yunokawa, M., et al. (2006). Expression of tumor-associated differentially expressed gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas. Tumour Biology, 27(5), 274–282. https://doi.org/10.1159/000094741.CrossRefPubMed Jin, H., Nagai, N., Shigemasa, K., Gu, L., Tanimoto, H., Yunokawa, M., et al. (2006). Expression of tumor-associated differentially expressed gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas. Tumour Biology, 27(5), 274–282. https://​doi.​org/​10.​1159/​000094741.CrossRefPubMed
141.
go back to reference Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L. J., O’Brien, T. J., et al. (2004). Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncology Reports, 11(6), 1153–1159.PubMed Shigemasa, K., Tian, X., Gu, L., Tanimoto, H., Underwood, L. J., O’Brien, T. J., et al. (2004). Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncology Reports, 11(6), 1153–1159.PubMed
148.
go back to reference Kusunoki, T., Nishida, S., Nakano, T., Funasaka, K., Kimoto, S., Murata, K., et al. (1995). Study on cathepsin B activity in human thyroid tumors. Auris Nasus Larynx, 22(1), 43–48.PubMedCrossRef Kusunoki, T., Nishida, S., Nakano, T., Funasaka, K., Kimoto, S., Murata, K., et al. (1995). Study on cathepsin B activity in human thyroid tumors. Auris Nasus Larynx, 22(1), 43–48.PubMedCrossRef
150.
go back to reference Yan, S., Sameni, M., & Sloane, B. F. (1998). Cathepsin B and human tumor progression. Biological Chemistry, 379(2), 113–123.PubMed Yan, S., Sameni, M., & Sloane, B. F. (1998). Cathepsin B and human tumor progression. Biological Chemistry, 379(2), 113–123.PubMed
152.
go back to reference Berquin, I. M., Ahram, M., & Sloane, B. F. (1997). Exon 2 of human cathepsin B derives from an Alu element. FEBS Letters, 419(1), 121–123.PubMedCrossRef Berquin, I. M., Ahram, M., & Sloane, B. F. (1997). Exon 2 of human cathepsin B derives from an Alu element. FEBS Letters, 419(1), 121–123.PubMedCrossRef
160.
go back to reference Chauhan, S. S., Goldstein, L. J., & Gottesman, M. M. (1991). Expression of cathepsin L in human tumors. Cancer Research, 51(5), 1478–1481.PubMed Chauhan, S. S., Goldstein, L. J., & Gottesman, M. M. (1991). Expression of cathepsin L in human tumors. Cancer Research, 51(5), 1478–1481.PubMed
163.
go back to reference Colella, R., & Casey, S. F. (2003). Decreased activity of cathepsins L + B and decreased invasive ability of PC3 prostate cancer cells. Biotechnic & Histochemistry, 78(2), 101–108.CrossRef Colella, R., & Casey, S. F. (2003). Decreased activity of cathepsins L + B and decreased invasive ability of PC3 prostate cancer cells. Biotechnic & Histochemistry, 78(2), 101–108.CrossRef
164.
173.
go back to reference Wyllie, A. H. (1997). Apoptosis and carcinogenesis. European Journal of Cell Biology, 73(3), 189–197.PubMed Wyllie, A. H. (1997). Apoptosis and carcinogenesis. European Journal of Cell Biology, 73(3), 189–197.PubMed
181.
go back to reference Kumar, S., Kinoshita, M., & Noda, M. (1997). Characterization of a mammalian cell death gene Nedd2. Leukemia, 11(Suppl 3), 385–386.PubMed Kumar, S., Kinoshita, M., & Noda, M. (1997). Characterization of a mammalian cell death gene Nedd2. Leukemia, 11(Suppl 3), 385–386.PubMed
184.
203.
205.
go back to reference Srinivasula, S. M., Ahmad, M., Guo, Y., Zhan, Y., Lazebnik, Y., Fernandes-Alnemri, T., et al. (1999). Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Research, 59(5), 999–1002.PubMed Srinivasula, S. M., Ahmad, M., Guo, Y., Zhan, Y., Lazebnik, Y., Fernandes-Alnemri, T., et al. (1999). Identification of an endogenous dominant-negative short isoform of caspase-9 that can regulate apoptosis. Cancer Research, 59(5), 999–1002.PubMed
208.
go back to reference Harada, K., Toyooka, S., Shivapurkar, N., Maitra, A., Reddy, J. L., Matta, H., et al. (2002). Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Research, 62(20), 5897–5901.PubMed Harada, K., Toyooka, S., Shivapurkar, N., Maitra, A., Reddy, J. L., Matta, H., et al. (2002). Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Research, 62(20), 5897–5901.PubMed
215.
go back to reference Stone, A. L., Kroeger, M., & Sang, Q. X. (1999). Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). Journal of Protein Chemistry, 18(4), 447–465.PubMedCrossRef Stone, A. L., Kroeger, M., & Sang, Q. X. (1999). Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). Journal of Protein Chemistry, 18(4), 447–465.PubMedCrossRef
224.
go back to reference Kodama, T., Ikeda, E., Okada, A., Ohtsuka, T., Shimoda, M., Shiomi, T., et al. (2004). ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. American Journal of Pathology, 165(5), 1743–1753. https://doi.org/10.1016/S0002-9440(10)63429-3.CrossRef Kodama, T., Ikeda, E., Okada, A., Ohtsuka, T., Shimoda, M., Shiomi, T., et al. (2004). ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. American Journal of Pathology, 165(5), 1743–1753. https://​doi.​org/​10.​1016/​S0002-9440(10)63429-3.CrossRef
226.
go back to reference Mino, N., Miyahara, R., Nakayama, E., Takahashi, T., Takahashi, A., Iwakiri, S., et al. (2009). A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. Journal of Surgical Oncology, 100(3), 267–272. https://doi.org/10.1002/jso.21313.CrossRefPubMed Mino, N., Miyahara, R., Nakayama, E., Takahashi, T., Takahashi, A., Iwakiri, S., et al. (2009). A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. Journal of Surgical Oncology, 100(3), 267–272. https://​doi.​org/​10.​1002/​jso.​21313.CrossRefPubMed
227.
go back to reference Narita, D., Anghel, A., Seclaman, E., Ilina, R., Cireap, N., & Ursoniu, S. (2010). Molecular profiling of ADAM12 gene in breast cancers. Romanian Journal of Morphology and Embryology, 51(4), 669–676.PubMed Narita, D., Anghel, A., Seclaman, E., Ilina, R., Cireap, N., & Ursoniu, S. (2010). Molecular profiling of ADAM12 gene in breast cancers. Romanian Journal of Morphology and Embryology, 51(4), 669–676.PubMed
235.
go back to reference Frohlich, C., Klitgaard, M., Noer, J. B., Kotzsch, A., Nehammer, C., Kronqvist, P., et al. (2013). ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochemical Journal, 452, 97–109. https://doi.org/10.1042/Bj20121558.CrossRef Frohlich, C., Klitgaard, M., Noer, J. B., Kotzsch, A., Nehammer, C., Kronqvist, P., et al. (2013). ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochemical Journal, 452, 97–109. https://​doi.​org/​10.​1042/​Bj20121558.CrossRef
238.
go back to reference Kang, Q., Cao, Y., & Zolkiewska, A. (2000). Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. Biochemical Journal, 352(Pt 3), 883–892.PubMedCentral Kang, Q., Cao, Y., & Zolkiewska, A. (2000). Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. Biochemical Journal, 352(Pt 3), 883–892.PubMedCentral
242.
243.
go back to reference Nath, D., Slocombe, P. M., Stephens, P. E., Warn, A., Hutchinson, G. R., Yamada, K. M., et al. (1999). Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. Journal of Cell Science, 112(Pt 4), 579–587.PubMed Nath, D., Slocombe, P. M., Stephens, P. E., Warn, A., Hutchinson, G. R., Yamada, K. M., et al. (1999). Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. Journal of Cell Science, 112(Pt 4), 579–587.PubMed
244.
247.
go back to reference Wotawa, A., Solier, S., Logette, E., Solary, E., & Corcos, L. (2002). Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Letters, 185(2), 181–189.PubMedCrossRef Wotawa, A., Solier, S., Logette, E., Solary, E., & Corcos, L. (2002). Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Letters, 185(2), 181–189.PubMedCrossRef
248.
go back to reference Solier, S., Lansiaux, A., Logette, E., Wu, J., Soret, J., Tazi, J., et al. (2004). Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Molecular Cancer Research, 2(1), 53–61.PubMed Solier, S., Lansiaux, A., Logette, E., Wu, J., Soret, J., Tazi, J., et al. (2004). Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Molecular Cancer Research, 2(1), 53–61.PubMed
Metadata
Title
Differential roles of protease isoforms in the tumor microenvironment
Authors
Chamikara Liyanage
Achala Fernando
Jyotsna Batra
Publication date
01-09-2019
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2019
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-019-09816-2

Other articles of this Issue 3/2019

Cancer and Metastasis Reviews 3/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine